CRX.L Regulatory News (CRX)

Cyprotex PLC ("Cyprotex" or the "Company")

Contract with U.S. Environmental Protection Agency

1 May 2013 - Cyprotex PLC (AIM: CRX), the specialist preclinical contract research organisation today announces that the U.S. Environmental Protection Agency (EPA) has awarded the Company the contract to obtain contractor services in support of the EPA's ongoing ToxCast Project relating to the Prioritization of Environmentally Relevant Chemicals. Cyprotex will be providing High Content Imaging Bioassay Analysis of the ToxCast Compound Library. The contract commenced on 25 April 2013 and runs for a period of five years. The delay in concluding this contract was referred to in the Chairman's comment in the Company's Interim Results announcement of 6 September 2012.

For further information:

Notes to Editors

About Cyprotex PLC

Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, MA in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotechs to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services , including our proprietary CellCiphr® toxicity prediction technology, and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, see www.cyprotex.com.